Adocia (ADOC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Adocia (ADOC) has a cash flow conversion efficiency ratio of 1.826x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€2.72 Million ≈ $3.18 Million USD) by net assets (€1.49 Million ≈ $1.74 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see ADOC company net worth for the company's overall valuation and market capitalisation.
Adocia - Cash Flow Conversion Efficiency Trend (2010–2025)
This chart illustrates how Adocia's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Adocia Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Adocia ranked by their cash flow conversion efficiency. Explore earnings quality score of Adocia to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Samsung Pharm
KO:001360
|
-0.013x |
|
MLRN Projects and Trade Ltd
TA:MLRN
|
-0.419x |
|
Frontier Energy Ltd
AU:FHE
|
-0.015x |
|
Air T Inc
NASDAQ:AIRT
|
-0.034x |
|
Semyung Electric Machinery Co.Ltd
KQ:017510
|
0.207x |
|
Dong Yang Pipe
KO:008970
|
-0.111x |
|
MEGA International Development Co Ltd
TWO:5529
|
0.360x |
|
Tah Kong Chemical Industrial
TWO:4706
|
0.003x |
Annual Cash Flow Conversion Efficiency for Adocia (2010–2025)
The table below shows the annual cash flow conversion efficiency of Adocia from 2010 to 2025. View ADOC share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €1.49 Million ≈ $1.74 Million |
€-6.53 Million ≈ $-7.63 Million |
-4.380x | -186.66% |
| 2024-12-31 | €-3.09 Million ≈ $-3.61 Million |
€-15.61 Million ≈ $-18.25 Million |
5.054x | +605.94% |
| 2023-12-31 | €-6.91 Million ≈ $-8.08 Million |
€-4.95 Million ≈ $-5.79 Million |
0.716x | -38.08% |
| 2022-12-31 | €-12.97 Million ≈ $-15.16 Million |
€-14.99 Million ≈ $-17.53 Million |
1.156x | -16.95% |
| 2021-12-31 | €-13.81 Million ≈ $-16.15 Million |
€-19.23 Million ≈ $-22.49 Million |
1.392x | +140.35% |
| 2020-12-31 | €6.33 Million ≈ $7.41 Million |
€-21.85 Million ≈ $-25.55 Million |
-3.450x | -902.03% |
| 2019-12-31 | €28.04 Million ≈ $32.78 Million |
€-9.65 Million ≈ $-11.29 Million |
-0.344x | -350.07% |
| 2018-12-31 | €45.85 Million ≈ $53.60 Million |
€6.31 Million ≈ $7.38 Million |
0.138x | +122.83% |
| 2017-12-31 | €36.86 Million ≈ $43.09 Million |
€-22.23 Million ≈ $-25.99 Million |
-0.603x | -96.29% |
| 2016-12-31 | €42.76 Million ≈ $49.99 Million |
€-13.14 Million ≈ $-15.36 Million |
-0.307x | -132.56% |
| 2015-12-31 | €47.05 Million ≈ $55.01 Million |
€-6.22 Million ≈ $-7.27 Million |
-0.132x | -101.08% |
| 2014-12-31 | €2.50 Million ≈ $2.93 Million |
€30.56 Million ≈ $35.73 Million |
12.200x | +2261.78% |
| 2013-12-31 | €19.13 Million ≈ $22.36 Million |
€-10.80 Million ≈ $-12.62 Million |
-0.564x | -1514.13% |
| 2012-12-31 | €23.03 Million ≈ $26.92 Million |
€919.00K ≈ $1.07 Million |
0.040x | +102.78% |
| 2011-12-31 | €4.33 Million ≈ $5.06 Million |
€-6.22 Million ≈ $-7.27 Million |
-1.436x | -209.61% |
| 2010-12-31 | €10.69 Million ≈ $12.49 Million |
€-4.96 Million ≈ $-5.79 Million |
-0.464x | -- |
About Adocia
Adocia SA, a clinical-stage biotechnology company, researches and develops therapeutic solutions for diabetes and obesity. Its proprietary BioChaperone technological platform provides molecular delivery of therapeutic proteins. The company provides BioChaperone Lispro U100 and U200, which are ultra-rapid formulations based on rapid prandial insulin lispro; BioChaperone Combo, a combination of act… Read more